193 related articles for article (PubMed ID: 18081539)
1. Current use and development of vaccines for Japanese encephalitis.
Beasley DW; Lewthwaite P; Solomon T
Expert Opin Biol Ther; 2008 Jan; 8(1):95-106. PubMed ID: 18081539
[TBL] [Abstract][Full Text] [Related]
2. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
[TBL] [Abstract][Full Text] [Related]
3. ChimeriVax-JE. Acambis.
Jones T
Curr Opin Investig Drugs; 2003 Aug; 4(8):1019-22. PubMed ID: 14508887
[TBL] [Abstract][Full Text] [Related]
4. Japanese encephalitis vaccines: current vaccines and future prospects.
Monath TP
Curr Top Microbiol Immunol; 2002; 267():105-38. PubMed ID: 12082985
[TBL] [Abstract][Full Text] [Related]
5. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
[TBL] [Abstract][Full Text] [Related]
6. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes.
Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
Clin Infect Dis; 2013 Jan; 56(2):267-70. PubMed ID: 23074319
[TBL] [Abstract][Full Text] [Related]
7. WHO working group on the quality, safety and efficacy of japanese encephalitis vaccines (live attenuated) for human use, Bangkok, Thailand, 21-23 February 2012.
Trent DW; Minor P; Jivapaisarnpong T; Shin J;
Biologicals; 2013 Nov; 41(6):450-7. PubMed ID: 23891495
[TBL] [Abstract][Full Text] [Related]
8. Japanese encephalitis: development of new candidate vaccines.
Bharati K; Vrati S
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):313-24. PubMed ID: 16597211
[TBL] [Abstract][Full Text] [Related]
9. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment for Japanese encephalitis vaccination.
Turtle L; Driver C
Hum Vaccin Immunother; 2018 Jan; 14(1):213-217. PubMed ID: 29244615
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
Capeding MR; Alberto ER; Bouckenooghe A; Laot TM; Chansinghakul D; Monfredo C; Machabert T; Feroldi E
J Infect Dis; 2018 Jan; 217(4):567-571. PubMed ID: 29325161
[TBL] [Abstract][Full Text] [Related]
12. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of IMOJEV ®--a recombinant Japanese encephalitis chimeric vaccine (JE-CV).
Appaiahgari MB; Vrati S
Expert Opin Biol Ther; 2012 Sep; 12(9):1251-63. PubMed ID: 22775524
[TBL] [Abstract][Full Text] [Related]
14. Control of Japanese encephalitis in Asia: the time is now.
Hills S; Martin R; Marfin A; Fischer M
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):901-4. PubMed ID: 24927959
[TBL] [Abstract][Full Text] [Related]
15. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
Beasley DW; Li L; Suderman MT; Guirakhoo F; Trent DW; Monath TP; Shope RE; Barrett AD
Vaccine; 2004 Sep; 22(27-28):3722-6. PubMed ID: 15315852
[TBL] [Abstract][Full Text] [Related]
16. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies.
Ferguson M; Johnes S; Li L; Heath A; Barrett A
Biologicals; 2008 Mar; 36(2):111-6. PubMed ID: 17892945
[TBL] [Abstract][Full Text] [Related]
17. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
19. Japanese encephalitis vaccines: moving away from the mouse brain.
Zanin MP; Webster DE; Martin JL; Wesselingh SL
Expert Rev Vaccines; 2003 Jun; 2(3):407-16. PubMed ID: 12903806
[TBL] [Abstract][Full Text] [Related]
20. A chimeric live attenuated vaccine against Japanese encephalitis.
Jones T
Expert Rev Vaccines; 2004 Jun; 3(3):243-8. PubMed ID: 15176941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
